IL317447A - Antibody drug conjugates - Google Patents

Antibody drug conjugates

Info

Publication number
IL317447A
IL317447A IL317447A IL31744724A IL317447A IL 317447 A IL317447 A IL 317447A IL 317447 A IL317447 A IL 317447A IL 31744724 A IL31744724 A IL 31744724A IL 317447 A IL317447 A IL 317447A
Authority
IL
Israel
Prior art keywords
drug conjugates
antibody drug
antibody
conjugates
drug
Prior art date
Application number
IL317447A
Other languages
Hebrew (he)
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of IL317447A publication Critical patent/IL317447A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL317447A 2022-06-09 2023-06-08 Antibody drug conjugates IL317447A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022097834 2022-06-09
PCT/CN2023/099148 WO2023237050A1 (en) 2022-06-09 2023-06-08 Antibody drug conjugates

Publications (1)

Publication Number Publication Date
IL317447A true IL317447A (en) 2025-02-01

Family

ID=89117517

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317447A IL317447A (en) 2022-06-09 2023-06-08 Antibody drug conjugates

Country Status (12)

Country Link
US (1) US20250099607A1 (en)
EP (1) EP4536666A4 (en)
JP (1) JP2025519421A (en)
KR (1) KR20250020660A (en)
CN (1) CN119317630A (en)
AU (1) AU2023283560A1 (en)
CA (1) CA3258612A1 (en)
CL (1) CL2024003768A1 (en)
CO (1) CO2025000056A2 (en)
IL (1) IL317447A (en)
MX (1) MX2024015179A (en)
WO (1) WO2023237050A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605459B2 (en) 2020-07-13 2026-04-21 Regeneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
WO2024138000A1 (en) * 2022-12-21 2024-06-27 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
FI131754B1 (en) * 2023-03-13 2025-11-11 Glykos Finland Oy ANTIBODY SEXATECAN CONJUGATE
AR134651A1 (en) * 2023-12-13 2026-02-04 Beigene Ltd ANTIBODY-DRUG CONJUGATE PLATFORMS
TW202543679A (en) 2023-12-29 2025-11-16 大陸商杭州尚健生物技術有限公司 An immune conjugate and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194567A1 (en) * 2011-04-21 2013-12-30 Seattle Genetics Inc Novel binder-drug conjugates (adcs) and their use
US10195288B2 (en) * 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (en) * 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
TWI871999B (en) * 2014-04-10 2025-02-01 日商第一三共股份有限公司 Anti-her3 antibody drug conjugate
US20170014524A1 (en) * 2015-07-15 2017-01-19 The California Institute For Biomedical Research Auristatin-antibody conjugates and uses thereof
SG11201906554RA (en) * 2017-01-17 2019-08-27 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
CN111065416B (en) * 2017-06-21 2024-09-13 芬兰吉利科斯有限公司 Hydrophilic linkers and conjugates thereof
UA130338C2 (en) * 2018-09-26 2026-01-28 Джянгсу Хенгруй Медісін Ко., Лтд. LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, METHOD FOR ITS PREPARATION AND ITS USE
JP7821733B2 (en) * 2020-01-22 2026-02-27 上海森輝医薬有限公司 Drug conjugate of eribulin derivative, its preparation method and medical application
US20230101735A1 (en) * 2020-01-22 2023-03-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
CN114845740B (en) * 2020-01-31 2026-06-02 先天制药公司 Cancer treatment
CA3175048A1 (en) * 2020-03-25 2021-09-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for antibody medicament conjugate
WO2021190586A1 (en) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 B7h3 antibody-exatecan analogue conjugate and pharmaceutical use thereof
WO2021190564A1 (en) * 2020-03-26 2021-09-30 上海翰森生物医药科技有限公司 Antibody-drug conjugate and medical use thereof
EP4227310A4 (en) * 2020-10-12 2024-11-06 Sichuan Baili Pharmaceutical Co. Ltd. CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF
CN116133694B (en) * 2020-10-14 2026-03-06 苏州盛迪亚生物医药有限公司 Anti-HER3 antibodies and anti-HER3 antibody-drug conjugates and their pharmaceutical uses
JP2024501121A (en) * 2020-11-25 2024-01-11 イナート・ファルマ・ソシエテ・アノニム cancer treatment
CN113816990B (en) * 2021-03-22 2023-08-22 联宁(苏州)生物制药有限公司 Modified amino acids and their use in ADCs
US12533419B2 (en) * 2021-07-19 2026-01-27 Mabplex International Co., Ltd. Antibody drug conjugate loaded with binary toxins and its application

Also Published As

Publication number Publication date
KR20250020660A (en) 2025-02-11
JP2025519421A (en) 2025-06-26
US20250099607A1 (en) 2025-03-27
WO2023237050A1 (en) 2023-12-14
CN119317630A (en) 2025-01-14
CA3258612A1 (en) 2023-12-14
MX2024015179A (en) 2025-02-10
AU2023283560A1 (en) 2025-01-23
CO2025000056A2 (en) 2025-01-23
EP4536666A1 (en) 2025-04-16
CL2024003768A1 (en) 2025-03-28
EP4536666A4 (en) 2026-08-12

Similar Documents

Publication Publication Date Title
IL313805A (en) Antibody drug conjugates
TWI925817B (en) Antibody drug conjugates
AU2021374958A9 (en) Antibody drug conjugates
PL4217398T3 (en) Anti-c-met antibody drug conjugates
IL299362A (en) Antibody-drug conjugates comprising anti-b7-h3 antibodies
CA3247730A1 (en) Hydrophilic linkers for antibody drug conjugates
PT3941946T (en) Claudin-6 antibodies and drug conjugates
IL311231A (en) Linkers for use in antibody drug conjugates
IL308795A (en) Anthracycline antibody conjugates
ZA202211123B (en) Drug antibody conjugates
IL308812A (en) Neodegrader-anti-cd33 antibody conjugates
IL316653A (en) Antibody drug conjugates
IL314622A (en) Humanized antibodies against nectin-2 and drug conjugates thereof
IL321698A (en) B7h3 antibody drug conjugates
SMT202400364T1 (en) Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
EP4130036A4 (en) Antibody drug conjugate
IL309048A (en) Anti-egfrviii antibody drug conjugates and uses thereof
IL326788A (en) Anti-Duple antibody conjugates
HK40116669A (en) Antibody drug conjugates
IL317285A (en) Anti-cd19 antibody drug conjugates
CA3288355A1 (en) Antibody drug conjugates
CA3278026A1 (en) Antibody drug conjugates
CA3303200A1 (en) Anti-doppel antibody drug conjugates
HK40124190A (en) Antibody drug conjugates
HK40117329A (en) Antibody drug conjugates